Skip to Content

E&W Blog

ICYMI: WATCH Foxx Talk Lower Costs, #MoreCures

Education and Labor Committee Republican Leader Virginia Foxx (R-NC), Energy and Commerce Committee Republican Leader Greg Walden (R-OR), Ways and Means Committee Republican Leader Kevin Brady (R-TX), and Judiciary Committee Republican Leader Doug Collins (R-GA) have introduced the Lower Costs, #MoreCures Act (H.R. 19), to lower drug costs for Americans without limiting access to cures.

Watch Republican Leader Foxx discuss the Lower Costs, #MoreCures Act at yesterday’s press conference:


“The Lowers Costs, More Cures Act will really deliver for the American people.
 
“The rising cost of prescription drugs is a serious problem that requires a serious approach. That is why Congressional efforts to bring down drug costs for the American people have been, and should continue to be, a collaborative and bipartisan effort.

“Unfortunately, Speaker Pelosi’s H.R. 3 sabotaged bipartisan efforts by Congress to enact a meaningful solution to this growing problem.
 
“The radical approach taken by H.R. 3 will eliminate choice and competition, jeopardize innovation, investment, and access to future cures – putting breakthrough treatments for diseases like Alzheimer’s, cancer, sickle cell disease, and others at risk as my colleagues have said today.
 
Democrats have said it is ‘worth it’ to lose new cures in order to pass H.R. 3. One cure lost is one too many.
 
“Congress shouldn’t be pursuing policies that will harm the health and well-being of American patients. And we shouldn’t destroy a system that allows the U.S. to lead the way in new cures and treatments.
 
“That is why we’ve introduced H.R. 19, the Lower Costs, More Cures Act. This bill contains measures that have bipartisan support in the House and the Senate, and as [Ranking Member] Walden has so eloquently talked about, really could be an answer to many many issues we’re facing.
 
The Lower Costs, More Cures Act is a commonsense, bipartisan solution that will help lower out-of-pocket costs, protect access to new medicines and cures, strengthen transparency and accountability, and champion competition.
 
“It is a great opportunity for us in the Congress to achieve something really really meaningful.
 
“Thank you very much.” 


                                                                                 ###

Stay Connected